Overview

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Enoxaparin
Enoxaparin sodium